family with sequence similarity 184 member BGenealiases: []
Q-omics provides the consensus-scored FAM184B profile across patient tissues and cancer cell-line models. FAM184B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM184B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM184B protein abundance shows 21,441 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where FAM184B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM184B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM184B survival associations across molecular data types. FAM184B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM184B RNA expression–survival associations across cancer types. High FAM184B expression shows unfavorable associations in KIRC, but favorable associations in BLCA, HNSC, BRCA, UCS and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM184B RNA expression.
This table summarizes FAM184B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM184B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM184B shows lower tumor expression in KIRC, KIRP, COAD and UCEC and higher tumor expression in KICH and CHOL. The KIRC box plot shows higher FAM184B RNA expression in normal versus tumor tissue (log2 FC = −0.763, t-test p < 0.001).
This table shows molecular features associated with FAM184B in patient tissues and cancer cell lines. In patient samples, FAM184B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM184B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
